Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I): wherein subscript m, L1, R1, and L1-R1 are as described herein.

Abstract: The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I): wherein subscript m, L1, R1, and L1-R1 are as described herein.

Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanism, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.

Abstract: Provided herein are compositions, delivery devices, and methods relating to the delivery of tetrabenazine and/or deuterated tetrabenazine, for example, continuous or substantially continuous delivery such as transdermal delivery, for the treatment of a hyperkinetic movement disorder. Also provided are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, pharmaceutical compositions comprising tetrabenazine and/or a deuterated tetrabenazine, methods of preparing the same, and methods of using the same for example, for the treatment of a hyperkinetic movement disorder.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: The present disclosure provides formulations suitable for topical administration that include compounds of formula (I): one or more excipients, and one or more optional additional components such as an acid or an antioxidant, wherein subscript m, L1, and R1 are as described herein. The formulations provided herein may be sufficiently stable that hydrolysis of the compound of formula (I) in the formulations is less than about 10% under a range of storage conditions. Processes for preparing the formulations and methods of treating vascular malformations with the formulations are also provided herein.

Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: Provided herein are film compositions comprising ketamine suitable for delivering ketamine across oral mucosal membranes. The film compositions can have various designs such as quick-release film, slow-release film, bilayer film that combines both a quick-release and slow-release film, or one-directional release film. Further are included methods of using the film compositions herein for the treatment of various diseases or disorders, such as pain and/or depression.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: Provided herein are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof. Also provided herein are pharmaceutical compositions, such as adhesive compositions, comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, for example, homogenously dispersed in an adhesive, such as a pressure sensitive adhesive. Further provided herein are methods of using the transdermal delivery devices or pharmaceutical compositions, for example, for treating a hyperkinetic movement disorder.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I): wherein subscript m, L1, R1, and L1-R1 are as described herein.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanisms, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.